Amgen to invest additional $300 million to boost US manufacturing footprint

Amgen is investing an additional $300 million in Puerto Rico to expand its Juncos biologics manufacturing facility, adding to $650 million announced last year and prior plans including $900 million in Ohio and $600 million in California. The move supports U.S. manufacturing expansion as drugmakers respond to President Trump’s proposed 100% tariffs on imported branded medicines. The company says the Puerto Rico site distributes medicines to more than 60 countries.

Analysis

This is less a one-off capex headline than a policy-induced rerating of domestic manufacturing optionality. For large branded-drug incumbents, incremental U.S. capacity becomes a quasi-hedge against tariff and pricing-rule uncertainty, which should support valuation multiples for firms with balance-sheet capacity to self-fund reshoring while squeezing smaller peers that rely on imported finished dose supply or third-party fill/finish. The second-order winner is likely the Puerto Rico industrial ecosystem: utilities, logistics, construction, and specialized labor all get a multi-year demand tailwind as pharma tries to localize without fully abandoning offshore cost advantages.

The market is likely underestimating the lag between announced capex and realized tariff immunity. The near-term earnings impact is mostly non-cash noise, while the real benefit is preserving distribution access and pricing leverage 12-36 months out. That means the trade is more about relative defense than immediate EPS upside: companies that can credibly show domestic redundancy should de-risk under tariff headlines, while those with constrained U.S. manufacturing footprints face higher procurement costs, slower approvals, or forced supply-chain rewiring.

Contrarian view: the policy may end up being less punitive than advertised because the biggest pharma names can negotiate around it, turning a tariff threat into a capital-allocation race rather than a margin-collapse event. If so, the broader basket reaction could fade after an initial relief rally in domestic capex names. The larger medium-term risk is margin dilution from duplicated capacity and lower utilization if multiple firms overbuild to buy political protection; that would cap long-run ROIC even as it reduces headline tariff exposure.

Key Decisions for Investors

• Long AMGN versus short a basket of imported-branded-drug exposure for 3-6 months; favor AMGN as a relative winner from policy insulation and balance-sheet-funded capacity, with upside if peers have to pay up for equivalent domestic redundancy.
• Initiate a pair trade: long large-cap domestic-capable pharma (AMGN, JNJ, MRK) / short smaller or higher-import-reliant healthcare names over 6-12 months; the thesis is that compliance cost and supply-chain friction will compress margins at the weaker end of the sector.
• Buy 6-12 month call spreads on AMGN on pullbacks of 2-4%; the setup is asymmetric because the market can re-rate the stock on policy shelter and manufacturing credibility, while downside is limited by its defensive fundamentals.
• For investors looking for a second-order beneficiary, consider a long on Puerto Rico-linked industrial/logistics exposure over 12-24 months; the capex wave should support construction, power, and transport activity beyond the headline drugmaker.
• Avoid chasing the broad pharma basket immediately after policy headlines; wait for a 1-2 week digestion period because the first move is likely to be sentiment-driven, while the fundamental winners will separate only as capex guidance and supply-chain plans become visible.